SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark launches first generic of Atovaquone Proguanil in UK

08 Feb 2013 Evaluate

Glenmark Generics (Europe) (GGEL) has launched the first generic of Atovaquone Proguanil in the UK following the revocation of the Malarone patent in the High court in the UK.

Atovaquone Proguanil is indicated for the prophylaxis and treatment of acute, uncomplicated p.falciparum malaria particularly where there is likely to be resistance. Based on IMS Health sales data for the 12 month period ending Sept 2012, Atovaquone Proguanil garnered sales of Euro 20.69 million in the UK.

The company has launched the drug after a judgment has been handed down in the case of Glenmark Generics (Europe) and Generics [UK] t/a Mylan v The Wellcome Foundation & Glaxo Group. The case involved the revocation of Glaxo’s patent for its anti-malarial product Malarone. Following proceedings in the High Court, Mr. Justice Arnold revoked Glaxo’s patent on the basis that it was obvious.

Glenmark Generics (Europe) is part of Glenmark Generics, which is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.

Glenmark Pharma Share Price

2392.60 -12.95 (-0.54%)
04-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.10
Dr. Reddys Lab 1287.95
Cipla 1334.85
Zydus Lifesciences 901.65
Lupin 2350.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×